Toviaz U.S. and Worldwide Sales

| Year  | United States |       |        | Worldwide |         |        |
|-------|---------------|-------|--------|-----------|---------|--------|
|       |               | Sales | Growth |           | Sales   | Growth |
| 2009  | \$            | 10.8  | n/a    | \$        | 59.0    | n/a    |
| 2010  | \$            | 54.7  | 406.5% | \$        | 137.0   | 132.2% |
| 2011  | \$            | 94.0  | 71.8%  | \$        | 187.0   | 36.5%  |
| 2012  | \$            | 115.2 | 22.6%  | \$        | 207.0   | 10.7%  |
| 2013  | \$            | 120.0 | 4.2%   | \$        | 236.0   | 14.0%  |
| 2014  | \$            | 133.0 | 10.8%  | \$        | 288.0   | 22.0%  |
| Total | \$            | 527.7 | n/a    | \$        | 1,114.0 | n/a    |

## Notes and sources:

Monetary values are in millions of \$U.S.

## U.S. sales:

2009-2010: UBS, "U.S. Pharmaceuticals," 8/24/2011, at 86, Table 83.

2011–2014: UBS, "U.S. Pharmaceuticals," 1/4/2016, at 90, Figure 82.

## Worldwide sales:

2009–2011: Pfizer Inc., Form 10-K, 2012, at Exhibit 13, p. 21.

2012–2014: Pfizer Inc., Form 10-K, 2015, at Exhibit 13, p. 21.